Did You Know...
...that after Walter Hunt patented the safety pin in 1849, he sold the rights to it for $400?
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7081482 | Use of β-adrenoceptor antagonists for the manufacture of a medicament for the treatment of disorders of the outer retina The invention is directed to the use of β-adrenoceptor antagonists for the manufacture of a medicament for the treatment of disorders of the outer retina. ... | 07/25/2006 |
| 7005446 | Use of AP-1 activators to treat glaucoma and ocular hypertension Compositions comprising AP-1 activators and methods of use for treating glaucoma and ocular hypertension are disclosed. ... | 02/28/2006 |
| 6960579 | Serotonergic 5HTreceptor compounds for treating ocular and CNS disorders Compounds with 5HT7 receptor affinity (some of which are novel) useful for lowering IOP, improving blood flow to the optic nerve head and the retina, providing neuroprotection, and treating retinal diseases are disclosed. The Compounds are also useful for... | 11/01/2005 |
| 6531480 | Non-peptide bradykinin receptor antagonists for use in treating ophthalmic diseases and disorders This invention relates to the topical ocular use of non-peptide bradykinin receptor antagonists for the treatment of human ocular pain, neovascularization, corneal haze, allergy and inflammatory diseases.... | 03/11/2003 |
| 6509355 | Treatment of disorders of the outer retina This invention is directed to the use of glutamate antagonists to treat the disorders of outer retina.... | 01/21/2003 |
| 6444676 | Use of PARP inhibitors in the treatment of glaucoma The invention provides pharmaceutical compositions containing PARP inhibitors and methods of using these compositions to prevent, treat or ameliorate glaucomatous retinopathy and/or optic neuropathy.... | 09/03/2002 |
| 6399058 | Methods for treating ocular diseases Methods, for lowering intraocular pressure by implanting in the anterior chamber encapsulated cells which secrete an intraocular pressure lowering substance.... | 06/04/2002 |
| 6316441 | Brinzolamide and brimonidine for treating glaucoma Methods and compositions for treating ocular conditions which find their etiology in compromised ocular blood flow with brinzolamide and brimonidine are disclosed.... | 11/13/2001 |
| 6303579 | Use of calpain inhibitors to treat ocular neural pathology The invention provides pharmaceutical compositions containing calpain inhibitors and methods of using these calpain inhibitors to prevent or ameliorate ocular neural tissue disease or damage.... | 10/16/2001 |
| 6300328 | Selective inhibitors of adenosine monophosphate deaminase for the treatment of optic nerve and retinal damage Selective AMPDA inhibitors for preventing and treating damage to the optic nerve and/or retina are disclosed.... | 10/09/2001 |
| 6297228 | Use of angiostatic steroids in photodynamic therapy Methods for treating ocular neovascularization using photodynamic therapy in combination with an angiostatic steriod are disclosed.... | 10/02/2001 |
| 6291479 | Use of NR2B-selective NMDA-receptor antagonists for the treatment of ophthalmic diseases The invention is directed to the use of improved NR2B antagonists for the prevention and treatment of retinal or optic nerve head damage in mammals. Compositions and methods are disclosed.... | 09/18/2001 |
| 6242441 | Use of brinzolamide to prevent visual field loss Methods for preventing or slowing visual field loss are disclosed.... | 06/05/2001 |
| 6242442 | Brinzolamide and brimonidine for treating ocular conditions Methods and compositions for treating ocular conditions which find their etiology in compromised ocular blood flow with brinzolamide and brimonidine are disclosed.... | 06/05/2001 |
| 6200990 | Neuroprotective agents having antioxidant and NMDA antagonist activity The invention is directed to the use of novel compounds, compositions and methods for the prevention and treatment of neuronal tissue damage in mammals. The novel compounds comprise an antioxidant and a NMDA antagonist activity.... | 03/13/2001 |
| 5360593 | Heat sterilization of labile antibiotics Disclosed is a process for heat sterilizing pharmaceuticals, cosmetics, foodstuffs and other materials, which are labile to oxidation by atmospheric oxygen at elevated temperature and labile to other degradative changes through interaction with volatiles ... | 11/01/1994 |
| 5221537 | Tissue irrigating solutions Irrigating solutions with thiol or disulfide containing compounds in physiologically acceptable salt solutions are described. The irrigating solutions are useful during surgery, particularly ophthalmic, neural, cardiovascular or otic surgery, to stabilize... | 06/22/1993 |
